Histone lysine methyltransferase SUV39H1 is a potent target for epigenetic therapy of hepatocellular carcinoma

Tetsuhiro Chiba(Chiba University), Osamu Yokosuka(Chiba University)

International Journal of Cancer

May 21, 2014

10.1002/ijc.28985

Cited by 117

Related Papers

Randomised, multicentre prospective trial of transarterial chemoembolisation (TACE) plus sorafenib as compared with TACE alone in patients with hepatocellular carcinoma: TACTICS trial

|Gut|2019|720

Pre-existing liver disease is associated with poor outcome in patients with SARS CoV2 infection; The APCOLIS Study (APASL COVID-19 Liver Injury Spectrum Study)

|Hepatology International|2020|295

New antiviral therapies for chronic hepatitis C

|Hepatology International|2010|105

Disulfiram Eradicates Tumor-Initiating Hepatocellular Carcinoma Cells in ROS-p38 MAPK Pathway-Dependent and -Independent Manners

|PLoS ONE|2014|79

Metformin, a Diabetes Drug, Eliminates Tumor-Initiating Hepatocellular Carcinoma Cells

|PLoS ONE|2013|74